The Journal of Heart and Lung Transplantation
Volume 25, Issue 9 , Pages 1003-1023 , September 2006

Optimal Pharmacologic and Non-pharmacologic Management of Cardiac Transplant Candidates: Approaches to Be Considered Prior to Transplant Evaluation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates—2006

Received 27 May 2006 ,Revised 27 May 2006 ,Accepted 16 June 2006.

References 

  1. Nieminen MS , Bohm M , Cowie MR , et al.   Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology . Eur Heart J . 2005;26:384–416
  2. Cosin J , Diez J . Torasemide in chronic heart failure: results of the TORIC study . Eur J Heart Fail . 2002;4:507–513
  3. Neuberg GW , Miller AB , O’Connor CM , et al.   Diuretic resistance predicts mortality in patients with advanced heart failure . Am Heart J . 2002;144:31–38
  4. De Bruyne LK . Mechanisms and management of diuretic resistance in congestive heart failure . Postgrad Med J . 2003;79:268–271
  5. Channer KS , McLean KA , Lawson-Matthew P , Richardson M . Combination diuretic treatment in severe heart failure: a randomised controlled trial . Br Heart J . 1994;71:146–150
  6. Dormans TP , Gerlag PG . Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure . Eur Heart J . 1996;17:1867–1874
  7. Eichhorn EJ , Bristow MR . Medical therapy can improve the biological properties of the chronically failing heart (A new era in the treatment of heart failure) . Circulation . 1996;94:2285–2296
  8. Swedberg K . Importance of neuroendocrine activation in chronic heart failure (Impact on treatment strategies) . Eur J Heart Fail . 2000;2:229–233
  9. Weber KT . Aldosterone in congestive heart failure . N Engl J Med . 2001;345:1689–1697
  10. Hunt SA , Baker DW , Chin MH , et al.   ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary . J Heart Lung Transplant . 2002;21:189–203
  11. Jessup M , Brozena S . Heart failure . N Engl J Med . 2003;348:2007–2018
  12. Remme WJ , Swedberg K . Guidelines for the diagnosis and treatment of chronic heart failure . Eur Heart J . 2001;22:1527–1560
  13. Bristow MR . Beta-adrenergic receptor blockade in chronic heart failure . Circulation . 2000;101:558–569
  14. Packer M . Neurohormonal interactions and adaptations in congestive heart failure . Circulation . 1988;77:721–730
  15. Stevenson LW . Beta-blockers for stable heart failure . N Engl J Med . 2002;346:1346–1347
  16. Flather MD , Yusuf S , Kober L , et al.  ACE-Inhibitor Myocardial Infarction Collaborative Group   Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients . Lancet . 2000;355:1575–1581
  17. The CONSENSUS Trial Study Group . Effects of enalapril on mortality in severe congestive heart failure (Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)) . N Engl J Med . 1987;316:1429–1435
  18. Packer M . Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure . Circulation . 1988;77:I-64–I-73
  19. Packer M , Lee WH , Kessler PD , Medina N , Yushak M , Gottlieb SS . Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure . J Am Coll Cardiol . 1987;10:837–844
  20. Packer M , Lee WH , Medina N , Yushak M , Kessler PD . Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure . Ann Intern Med . 1987;106:346–354
  21. Mann JF , Gerstein HC , Pogue J , Bosch J , Yusuf S . Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial . Ann Intern Med . 2001;134:629–636
  22. Kittleson M , Hurwitz S , Shah MR , et al.   Development of circulatory–renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality . J Am Coll Cardiol . 2003;41:2029–2035
  23. Gring CN , Francis GS . A hard look at angiotensin receptor blockers in heart failure . J Am Coll Cardiol . 2004;44:1841–1846
  24. McMurray JJ , Pfeffer MA , Swedberg K , Dzau VJ . Which inhibitor of the renin–angiotensin system should be used in chronic heart failure and acute myocardial infarction? . Circulation . 2004;110:3281–3288
  25. Granger CB , McMurray JJ , Yusuf S , et al.   Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial . Lancet . 2003;362:772–776
  26. Maggioni AP , Anand I , Gottlieb SO , Latini R , Tognoni G , Cohn JN . Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors . J Am Coll Cardiol . 2002;40:1414–1421
  27. Pfeffer MA , McMurray JJ , Velazquez EJ , et al.   Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both . N Engl J Med . 2003;349:1893–1906
  28. Cohn JN , Tognoni G . A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure . N Engl J Med . 2001;345:1667–1675
  29. McMurray JJ , Ostergren J , Swedberg K , et al.   Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial . Lancet . 2003;362:767–771
  30. Pitt B , Zannad F , Remme WJ , et al.  Randomized Aldactone Evaluation Study Investigators   The effect of spironolactone on morbidity and mortality in patients with severe heart failure . N Engl J Med . 1999;341:709–717
  31. Pitt B , Remme W , Zannad F , et al.   Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction . N Engl J Med . 2003;348:1309–1321
  32. Juurlink DN , Mamdani MM , Lee DS , et al.   Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study . N Engl J Med . 2004;351:543–551
  33. Metra M , Nodari S , Dei CL . Current guidelines in the pharmacological management of chronic heart failure . J Renin Angiotensin Aldosterone Syst . 2004;5(suppl 1):S11–S16
  34. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial . Lancet . 1999;353:9–13
  35. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) . Lancet . 1999;353:2001–2007
  36. Packer M , Coats AJ , Fowler MB , et al.   Effect of carvedilol on survival in severe chronic heart failure . N Engl J Med . 2001;344:1651–1658
  37. Erdmann E , Lechat P , Verkenne P , Wiemann H . Results from post hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure . Eur J Heart Fail . 2001;3:469–479
  38. Goldstein S , Fagerberg B , Hjalmarson A , et al.   Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study . J Am Coll Cardiol . 2001;38:932–938
  39. Krum H , Roecker EB , Mohacsi P , et al.   Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study . JAMA . 2003;289:712–718
  40. Krum H , Ninio D , MacDonald P . Baseline predictors of tolerability to carvedilol in patients with chronic heart failure . Heart . 2000;84:615–619
  41. Macdonald PS , Keogh AM , Aboyoun CL , Lund M , Amor R , McCaffrey DJ . Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure . J Am Coll Cardiol . 1999;33:924–931
  42. Rouleau JL , Roecker EB , Tendera M , et al.   Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study . J Am Coll Cardiol . 2004;43:1423–1429
  43. Metra M , Giubbini R , Nodari S , Boldi E , Modena MG , Dei CL . Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol . Circulation . 2001;102:546–551
  44. Poole-Wilson PA , Swedberg K , Cleland JG , et al.   Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial . Lancet . 2003;362:7–13
  45. Flather MD , Shibata MC , Coats AJ , et al.   Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) . Eur Heart J . 2005;26:215–225
  46. Gattis WA , O’Connor CM , Leimberger JD , Felker GM , Adams KF , Gheorghiade M . Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure . Am J Cardiol . 2003;91:169–174
  47. Metra M , Torp-Pedersen C , Charlesworth A . Should beta-blocker therapy be reduced or withdrawn in patients with worsening heart failure? (Insights from COMET) . Circulation . 2004;110:III-430
  48. Nohria A , Lewis E , Stevenson LW . Medical management of advanced heart failure . JAMA . 2002;287:628–640
  49. Taylor AL , Ziesche S , Yancy C , et al.   Combination of isosorbide dinitrate and hydralazine in blacks with heart failure . N Engl J Med . 2004;351:2049–2057
  50. Packer M , Gheorghiade M , Young JB , et al.  RADIANCE Study   Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors . N Engl J Med . 1993;329:1–7
  51. Uretsky BF , Young JB , Shahidi FE , Yellen LG , Harrison MC , Jolly MK  PROVED Investigative Group . Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial . J Am Coll Cardiol . 1993;22:955–962
  52. DiBianco R , Shabetai R , Kostuk W , Moran J , Schlant RC , Wright R . A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure . N Engl J Med . 1989;320:677–683
  53. The Digitalis Investigation Group . The effect of digoxin on mortality and morbidity in patients with heart failure . N Engl J Med . 1997;336:525–533
  54. Rathore SS , Wang Y , Krumholz HM . Sex-based differences in the effect of digoxin for the treatment of heart failure . N Engl J Med . 2002;347:1403–1411
  55. Farshi R , Kistner D , Sarma JS , Longmate JA , Singh BN . Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens . J Am Coll Cardiol . 1999;33:304–310
  56. Packer M , Fowler MB , Roecker EB , et al.   Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study . Circulation . 2002;106:2194–2199
  57. Eichhorn EJ , Lukas MA , Wu B , Shusterman N . Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart failure . Am J Cardiol . 2000;86: 1032–1
  58. Adamopoulos S , Parissis JT , Kremastinos DT . New aspects for the role of physical training in the management of patients with chronic heart failure . Int J Cardiol . 2003;90:1–14
  59. Coats AJ , Adamopoulos S , Radaelli A , et al.   Controlled trial of physical training in chronic heart failure (Exercise performance, hemodynamics, ventilation, and autonomic function) . Circulation . 1992;85:2119–2131
  60. Malfatto G , Branzi G , Riva B , Sala L , Leonetti G , Facchini M . Recovery of cardiac autonomic responsiveness with low-intensity physical training in patients with chronic heart failure . Eur J Heart Fail . 2002;4:159–166
  61. Pina IL , Apstein CS , Balady GJ , et al.   Exercise and heart failure: a statement from the American Heart Association Committee on exercise, rehabilitation, and prevention . Circulation . 2003;107:1210–1225
  62. Leon AS , Franklin BA , Costa F , et al.   Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation . Circulation . 2005;111:369–376
  63. Taylor RS , Brown A , Ebrahim S , et al.   Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials . Am J Med . 2004;116:682–692
  64. Thompson PD , Franklin BA . From case report to meta-analysis—additional evidence for the benefits of exercise training in cardiac patients . Am J Med . 2004;116:714–716
  65. Malfatto G , Branzi G , Riva B , Sala L , Leonetti G , Facchini M . Recovery of cardiac autonomic responsiveness with low-intensity physical training in patients with chronic heart failure . Eur J Heart Fail . 2002;4:159–166
  66. Belardinelli R , Georgiou D , Cianci G , Purcaro A . Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome . Circulation . 1999;99:1173–1182
  67. Cahalin LP , Semigran MJ , Dec GW . Inspiratory muscle training in patients with chronic heart failure awaiting cardiac transplantation: results of a pilot clinical trial . Phys Ther . 1997;77:830–838
  68. Gottlieb SS , Fisher ML , Freudenberger R , et al.   Effects of exercise training on peak performance and quality of life in congestive heart failure patients . J Card Fail . 1999;5:188–194
  69. Hambrecht R , Fiehn E , Weigl C , et al.   Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure . Circulation . 1998;98:2709–2715
  70. Kiilavuori K , Naveri H , Leinonen H , Harkonen M . The effect of physical training on hormonal status and exertional hormonal response in patients with chronic congestive heart failure . Eur Heart J . 1999;20:456–464
  71. McConnell TR , Mandak JS , Sykes JS , Fesniak H , Dasgupta H . Exercise training for heart failure patients improves respiratory muscle endurance, exercise tolerance, breathlessness, and quality of life . J Cardiopulm Rehabil . 2003;23:10–16
  72. McKelvie RS , Teo KK , Roberts R , et al.   Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT) . Am Heart J . 2002;144:23–30
  73. Pietila M , Malminiemi K , Vesalainen R , et al.   Exercise training in chronic heart failure: beneficial effects on cardiac (11)C-hydroxyephedrine PET, autonomic nervous control, and ventricular repolarization . J Nucl Med . 2002;43:773–779
  74. Pu CT , Johnson MT , Forman DE , et al.   Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure . J Appl Physiol . 2001;90:2341–2350
  75. Schulze PC , Gielen S , Schuler G , Hambrecht R . Chronic heart failure and skeletal muscle catabolism: effects of exercise training . Int J Cardiol . 2002;85:141–149
  76. Smart N , Marwick TH . Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity . Am J Med . 2004;116:693–706
  77. Ades PA , Green NM , Coello CE . Effects of exercise and cardiac rehabilitation on cardiovascular outcomes . Cardiol Clin . 2003;21:435–448
  78. Stewart KJ , Badenhop D , Brubaker PH , Keteyian SJ , King M . Cardiac rehabilitation following percutaneous revascularization, heart transplant, heart valve surgery, and for chronic heart failure . Chest . 2003;123:2104–2111
  79. Piepoli MF , Davos C , Francis DP , Coats AJ . Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH) . BMJ . 2004;328:189
  80. Erbs S , Linke A , Gielen S , et al.   Exercise training in patients with severe chronic heart failure: impact on left ventricular performance and cardiac size (A retrospective analysis of the Leipzig Heart Failure Training Trial) . Eur J Cardiovasc Prev Rehabil . 2003;10:336–344
  81. Georgiou D , Chen Y , Appadoo S , et al.   Cost-effectiveness analysis of long-term moderate exercise training in chronic heart failure . Am J Cardiol . 2001;87:984–988
  82. Giannuzzi P , Temporelli PL , Corra U , Tavazzi L . Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) Trial . Circulation . 2003;108:554–559
  83. Hambrecht R , Gielen S , Linke A , et al.   Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial . JAMA . 2000;283:3095–3101
  84. Quan SF , Gersh BJ . Cardiovascular consequences of sleep-disordered breathing: past, present and future: report of a workshop from the National Center on Sleep Disorders Research and the National Heart, Lung, and Blood Institute . Circulation . 2004;109:951–957
  85. Leung RS , Bradley TD . Sleep apnea and cardiovascular disease . Am J Respir Crit Care Med . 2001;164:2147–2165
  86. Ponikowski P , Chua TP , Piepoli M , et al.   Chemoreceptor dependence of very low frequency rhythms in advanced chronic heart failure . Am J Physiol . 1997;272:H438–H447
  87. Younes M . The pathophysiologic basis of central apnea and periodic breathing . Curr Pulmonol . 1989;19:265–326
  88. Javaheri S , Parker TJ , Liming JD , et al.   Sleep apnea in 81 ambulatory male patients with stable heart failure (Types and their prevalences, consequences, and presentations) . Circulation . 1998;97:2154–2159
  89. Sin DD , Fitzgerald F , Parker JD , Newton G , Floras JS , Bradley TD . Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure . Am J Respir Crit Care Med . 1999;160:1101–1106
  90. Laaban JP , Pascal-Sebaoun S , Bloch E , Orvoen-Frija E , Oppert JM , Huchon G . Left ventricular systolic dysfunction in patients with obstructive sleep apnea syndrome . Chest . 2002;122:1133–1138
  91. Parker JD , Brooks D , Kozar LF , et al.   Acute and chronic effects of airway obstruction on canine left ventricular performance . Am J Respir Crit Care Med . 1999;160:1888–1896
  92. Carlson JT , Hedner J , Elam M , Ejnell H , Sellgren J , Wallin BG . Augmented resting sympathetic activity in awake patients with obstructive sleep apnea . Chest . 1993;103:1763–1768
  93. Lanfranchi PA , Braghiroli A , Bosimini E , et al.   Prognostic value of nocturnal Cheyne–Stokes respiration in chronic heart failure . Circulation . 1999;99:1435–1440
  94. Wilcox I , McNamara SG , Wessendorf T , Willson GN , Piper AJ , Sullivan CE . Prognosis and sleep disordered breathing in heart failure . Thorax . 1998;53(suppl 3):S33–S36
  95. Javaheri S . Effects of continuous positive airway pressure on sleep apnea and ventricular irritability in patients with heart failure . Circulation . 2000;101:392–397
  96. Lanfranchi PA , Somers VK , Braghiroli A , Corra U , Eleuteri E , Giannuzzi P . Central sleep apnea in left ventricular dysfunction: prevalence and implications for arrhythmic risk . Circulation . 2003;107:727–732
  97. Krachman SL , D’Alonzo GE , Berger TJ , Eisen HJ . Comparison of oxygen therapy with nasal continuous positive airway pressure on Cheyne–Stokes respiration during sleep in congestive heart failure . Chest . 1999;116:1550–1557
  98. Bradley TD , Holloway RM , McLaughlin PR , Ross BL , Walters J , Liu PP . Cardiac output response to continuous positive airway pressure in congestive heart failure . Am Rev Respir Dis . 1992;145:377–382
  99. Buckle P , Millar T , Kryger M . The effect of short-term nasal CPAP on Cheyne–Stokes respiration in congestive heart failure . Chest . 1992;102:31–35
  100. Kaneko Y , Floras JS , Usui K , et al.   Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea . N Engl J Med . 2003;348:1233–1241
  101. Malone S , Liu PP , Holloway R , Rutherford R , Xie A , Bradley TD . Obstructive sleep apnoea in patients with dilated cardiomyopathy: effects of continuous positive airway pressure . Lancet . 1991;338:1480–1484
  102. Mehta S , Liu PP , Fitzgerald FS , Allidina YK , Douglas BT . Effects of continuous positive airway pressure on cardiac volumes in patients with ischemic and dilated cardiomyopathy . Am J Respir Crit Care Med . 2000;161:128–134
  103. Naughton MT , Liu PP , Bernard DC , Goldstein RS , Bradley TD . Treatment of congestive heart failure and Cheyne–Stokes respiration during sleep by continuous positive airway pressure . Am J Respir Crit Care Med . 1995;151:92–97
  104. Naughton MT , Rahman MA , Hara K , Floras JS , Bradley TD . Effect of continuous positive airway pressure on intrathoracic and left ventricular transmural pressures in patients with congestive heart failure . Circulation . 1995;91:1725–1731
  105. Naughton MT , Benard DC , Liu PP , Rutherford R , Rankin F , Bradley TD . Effects of nasal CPAP on sympathetic activity in patients with heart failure and central sleep apnea . Am J Respir Crit Care Med . 1995;152:473–479
  106. Tkacova R , Liu PP , Naughton MT , Bradley TD . Effect of continuous positive airway pressure on mitral regurgitant fraction and atrial natriuretic peptide in patients with heart failure . J Am Coll Cardiol . 1997;30:739–745
  107. Pepperell JC , Maskell NA , Jones DR , et al.   A randomized controlled trial of adaptive ventilation for Cheyne–Stokes breathing in heart failure . Am J Respir Crit Care Med . 2001;168:1109–1114
  108. Schadlich S , Konigs I , Kalbitz F , Blankenburg T , Busse HJ , Schutte W . Cardiac efficiency in patients with Cheyne–Stokes respiration as a result of heart insufficiency during long-term nasal respiratory treatment with adaptive servo ventilation (AutoSet CS) . [in German] Z Kardiol . 2004;93:454–462
  109. Teschler H , Dohring J , Wang YM , Berthon-Jones M . Adaptive pressure support servo-ventilation: a novel treatment for Cheyne–Stokes respiration in heart failure . Am J Respir Crit Care Med . 2001;164:614–619
  110. Sin DD , Logan AG , Fitzgerald FS , Liu PP , Bradley TD . Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne–Stokes respiration . Circulation . 2000;102:61–66
  111. Bradley TD , Logan AG , Kimoff RJ , et al.   Continuous positive airway pressure for central sleep apnea and heart failure . N Engl J Med . 2005;353:2025–2033
  112. Cohn JN , Franciosa JA . Vasodilator therapy of cardiac failure (second of two parts) . N Engl J Med . 1977;297:254–258
  113. Cotter G , Metzkor E , Kaluski E , et al.   Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema . Lancet . 1998;351:389–393
  114. Colucci WS , Elkayam U , Horton DP , et al.  Nesiritide Study Group   Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure . N Engl J Med . 2000;343:246–253
  115. Hobbs RE , Mills RM , Young JB . An update on nesiritide for treatment of decompensated heart failure . Expert Opin Investig Drugs . 2001;10:935–942
  116. Mills RM , Hobbs RE , Young JB . “BNP” for heart failure: role of nesiritide in cardiovascular therapeutics . Congest Heart Fail . 2002;8:270–273
  117. Protter AA , Wallace AM , Ferraris VA , Weishaar RE . Relaxant effect of human brain natriuretic peptide on human artery and vein tissue . Am J Hypertens . 1996;9:432–436
  118. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial . JAMA . 2002;287:1531–1540
  119. Abramson BL , Ando S , Notarius CF , Rongen GA , Floras JS . Effect of atrial natriuretic peptide on muscle sympathetic activity and its reflex control in human heart failure . Circulation . 1999;99:1810–1815
  120. Burger AJ , Elkayam U , Neibaur MT , et al.   Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy . Am J Cardiol . 2001;88:35–39
  121. Burger AJ , Horton DP , LeJemtel T , et al.   Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study . Am Heart J . 2002;144:1102–1108
  122. Marcus LS , Hart D , Packer M , et al.   Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure (A double-blind, placebo-controlled, randomized crossover trial) . Circulation . 1996;94:3184–3189
  123. Abraham WT , Lowes BD , Ferguson DA , et al.   Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure . J Card Fail . 1998;4:37–44
  124. Wang DJ , Dowling TC , Meadows D , et al.   Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine . Circulation . 2004;110:1620–1625
  125. Sackner-Bernstein JD , Skopicki HA , Aaronson KD . Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure . Circulation . 2005;111:1487–1491
  126. Keating GM , Goa KL . Nesiritide: a review of its use in acute decompensated heart failure . Drugs . 2003;63:47–70
  127. Sackner-Bernstein JD , Kowalski M , Fox M , Aaronson K . Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials . JAMA . 2005;293:1900–1905
  128. Yancy CW , Saltzberg MT , Berkowitz RL , et al.   Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial) . Am J Cardiol . 2004;94:595–601
  129. Dorn GW , Molkentin JD . Manipulating cardiac contractility in heart failure: data from mice and men . Circulation . 2004;109:150–158
  130. Feldman AM . Classification of positive inotropic agents . J Am Coll Cardiol . 1993;22:1223–1227
  131. Stevenson LW . Clinical use of inotropic therapy for heart failure: looking backward or forward? (Part I: inotropic infusions during hospitalization) . Circulation . 2003;108:367–372
  132. Cowley AJ , Skene AM  Enoximone Investigators . Treatment of severe heart failure: quantity or quality of life? (A trial of enoximone) . Br Heart J . 1994;72:226–230
  133. Sharma M , Teerlink JR . A rational approach for the treatment of acute heart failure: current strategies and future options . Curr Opin Cardiol . 2004;19:254–263
  134. Thackray S , Easthaugh J , Freemantle N , Cleland JG . The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure—a meta-regression analysis . Eur J Heart Fail . 2002;4:515–529
  135. Pozen RG , DiBianco R , Katz RJ , Bortz R , Myerburg RJ , Fletcher RD . Myocardial metabolic and hemodynamic effects of dobutamine in heart failure complicating coronary artery disease . Circulation . 1981;63:1279–1285
  136. Campana C , Scelsi L , Serio A . Infusion therapy in severe heart failure (A reappraisal) . Ital Heart J . 2003;4(suppl 2):15S–21S
  137. Chatterjee K , De MT . Role of nonglycosidic inotropic agents: indications, ethics, and limitations . Med Clin N Am . 2003;87:391–418
  138. Felker GM , O’Connor CM . Inotropic therapy for heart failure: an evidence-based approach . Am Heart J . 2001;142:393–401
  139. Bristow MR . Changes in myocardial and vascular receptors in heart failure . J Am Coll Cardiol . 1993;22(suppl A): 61A–71
  140. Bristow MR . Mechanism of action of beta-blocking agents in heart failure . Am J Cardiol . 1997;80: 26L–40
  141. Bristow MR , Ginsburg R , Minobe W , et al.   Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts . N Engl J Med . 1982;307:205–211
  142. Fowler MB , Laser JA , Hopkins GL , Minobe W , Bristow MR . Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response . Circulation . 1986;74:1290–1302
  143. Goldberg LI . Cardiovascular and renal actions of dopamine: potential clinical applications . Pharmacol Rev . 1972;24:1–29
  144. Goldberg LI , Volkman PH , Kohli JD . A comparison of the vascular dopamine receptor with other dopamine receptors . Annu Rev Pharmacol Toxicol . 1978;18:57–79
  145. Lokhandwala MF , Barrett RJ . Cardiovascular dopamine receptors: physiological, pharmacological and therapeutic implications . J Auton Pharmacol . 1982;2:189–215
  146. Rajfer SI , Goldberg LI . Dopamine in the treatment of heart failure . Eur Heart J . 1982;3(suppl D):103–106
  147. Lowes BD , Tsvetkova T , Eichhorn EJ , Gilbert EM , Bristow MR . Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol . Int J Cardiol . 2001;81:141–149
  148. Metra M , Nodari S , D’Aloia A , et al.   Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol . J Am Coll Cardiol . 2002;40:1248–1258
  149. Akhtar N , Mikulic E , Cohn JN , Chaudhry MH . Hemodynamic effect of dobutamine in patients with severe heart failure . Am J Cardiol . 1975;36:202–205
  150. Leier CV , Webel J , Bush CA . The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure . Circulation . 1977;56:468–472
  151. Meyer SL , Curry GC , Donsky MS , Twieg DB , Parkey RW , Willerson JT . Influence of dobutamine on hemodynamics and coronary blood flow in patients with and without coronary artery disease . Am J Cardiol . 1976;38:103–108
  152. Unverferth DA , Blanford M , Kates RE , Leier CV . Tolerance to dobutamine after a 72 hour continuous infusion . Am J Med . 1980;69:262–266
  153. Bristow MR , Port JD , Hershberger RE , Gilbert EM , Feldman AM . The beta-adrenergic receptor–adenylate cyclase complex as a target for therapeutic intervention in heart failure . Eur Heart J . 1989;10(suppl B):45–54
  154. Colucci WS , Denniss AR , Leatherman GF , et al.   Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure (Dose–response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition) . J Clin Invest . 1988;81:1103–1110
  155. Burger AJ , Horton DP , LeJemtel T , et al.   Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study . Am Heart J . 2002;144:1102–1108
  156. Puddu PE , Papalia U , Schiariti M , Usta C . Dobutamine effects on spontaneous variability of ventricular arrhythmias in patients with severe chronic heart failure: the Italian Multicenter Study . Ital Heart J . 2004;693–701
  157. Baim DS , McDowell AV , Cherniles J , et al.   Evaluation of a new bipyridine inotropic agent—milrinone—in patients with severe congestive heart failure . N Engl J Med . 1983;309:748–756
  158. Cowley AJ , Stainer K , Fullwood L , Muller AF , Hampton JR . Effects of enoximone in patients with heart failure uncontrolled by captopril and diuretics . Int J Cardiol . 1990;28(suppl 1):S45–S52
  159. Herrmann HC , Ruddy TD , Dec GW , Strauss HW , Boucher CA , Fifer MA . Diastolic function in patients with severe heart failure: comparison of the effects of enoximone and nitroprusside . Circulation . 1987;75:1214–1221
  160. Klocke RK , Mager G , Kux A , Hopp HW , Hilger HH . Effects of a twenty-four-hour milrinone infusion in patients with severe heart failure and cardiogenic shock as a function of the hemodynamic initial condition . Am Heart J . 1991;121:1965–1973
  161. Rettig GF , Schieffer HJ . Acute effects of intravenous milrinone in heart failure . Eur Heart J . 1989;10(suppl C):39–43
  162. Luo W , Grupp IL , Harrer J , et al.   Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation . Circ Res . 1994;75:401–409
  163. Anderson JL . Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States . Am Heart J . 1991;121:1956–1964
  164. Gage J , Rutman H , Lucido D , LeJemtel TH . Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure . Circulation . 1986;74:367–373
  165. Gilbert EM , Hershberger RE , Wiechmann RJ , Movsesian MA , Bristow MR . Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart . Chest . 1995;108:1524–1532
  166. Uretsky BF , Lawless CE , Verbalis JG , Valdes AM , Kolesar JA , Reddy PS . Combined therapy with dobutamine and amrinone in severe heart failure (Improved hemodynamics and increased activation of the renin–angiotensin system with combined intravenous therapy) . Chest . 1987;92:657–662
  167. Bristow MR , Shakar SF , Linseman JV , Lowes BD . Inotropes and beta-blockers: is there a need for new guidelines? . J Card Fail . 2001;7(suppl 1):8–12
  168. Hauptman PJ , Woods D , Prirzker MR . Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure . Clin Cardiol . 2002;25:247–249
  169. Kumar A , Choudhary G , Antonio C , et al.   Carvedilol titration in patients with congestive heart failure receiving inotropic therapy . Am Heart J . 2001;142:512–515
  170. Shakar SF , Bristow MR . Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents . Curr Cardiol Rep . 2001;3:224–231
  171. Shakar SF , Abraham WT , Gilbert EM , et al.   Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure . J Am Coll Cardiol . 1998;31:1336–1340
  172. Zampino M , O’Connor CM , Gattis WA , Adams KF , Gheorghiade M . Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial . Am Heart J . 2003;145(suppl):S62–S66
  173. Edes I , Kiss E , Kitada Y , et al.   Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart . Circ Res . 1995;77:107–113
  174. Endoh M . Mechanism of action of Ca2+ sensitizers—update 2001 . Cardiovasc Drugs Ther . 2001;15:397–403
  175. Hasenfuss G , Pieske B , Castell M , Kretschmann B , Maier LS , Just H . Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium . Circulation . 1998;98:2141–2147
  176. Slawsky MT , Colucci WS , Gottlieb SS , et al.  Study investigators   Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure . Circulation . 2000;102:2222–2227
  177. Cleland JG , McGowan J . Levosimendan: a new era for inodilator therapy for heart failure? . Curr Opin Cardiol . 2002;17:257–265
  178. Follath F , Cleland JG , Just H , et al.   Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial . Lancet . 2002;360:196–202
  179. Nieminen MS , Akkila J , Hasenfuss G , et al.   Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure . J Am Coll Cardiol . 2000;36:1903–1912
  180. Kivikko M , Lehtonen L , Colucci WS . Sustained hemodynamic effects of intravenous levosimendan . Circulation . 2003;107:81–86
  181. Lehtonen L , Sundberg S . The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects . Eur J Clin Pharmacol . 2002;58:449–452
  182. Innes CA , Wagstaff AJ . Levosimendan: a review of its use in the management of acute decompensated heart failure . Drugs . 2003;63:2651–2671
  183. Brozena SC , Twomey C , Goldberg LR , et al.   A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home . J Heart Lung Transplant . 2004;23:1082–1086
  184. Canver CC , Chanda J . Milrinone for long-term pharmacologic support of the status 1 heart transplant candidates . Ann Thorac Surg . 2000;69:1823–1826
  185. Capomolla S , Febo O , Opasich C , et al.   Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome . Eur J Heart Fail . 2001;3:601–610
  186. Rapezzi C , Bracchetti G , Branzi A , Magnani B . The case against outpatient parenteral inotropic therapy for advanced heart failure . J Heart Lung Transplant . 2000;19(suppl):S58–S63
  187. Upadya S , Lee FA , Saldarriaga C , et al.   Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure . J Heart Lung Transplant . 2004;23:466–472
  188. Jimenez J , Jara J , Bednar B , Bauerlein J , Mallon S . Long-term (>8 weeks) home inotropic therapy as destination therapy in patients with advanced heart failure or as bridge to heart transplantation . Int J Cardiol . 2005;99:47–50
  189. Lopez-Candales AL , Carron C , Schwartz J . Need for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropes . Clin Cardiol . 2004;27:23–28
  190. Mehra MR , Uber PA . The dilemma of late-stage heart failure (Rationale for chronic parenteral inotropic support) . Cardiol Clin . 2001;19:627–636
  191. Miller LW , Merkle EJ , Herrmann V . Outpatient dobutamine for end-stage congestive heart failure . Crit Care Med . 1990;18(suppl):S30–S33
  192. Pantilat SZ , Steimle AE . Palliative care for patients with heart failure . JAMA . 2004;291:2476–2482
  193. Sindone AP , Keogh AM , Macdonald PS , McCosker CJ , Kaan AF . Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy . Am Heart J . 1997;134:889–900
  194. Stevenson LW . Clinical use of inotropic therapy for heart failure: looking backward or forward? (Part II: chronic inotropic therapy) . Circulation . 2003;108:492–497
  195. Stevenson LW , Miller LW , Svigne-Nickens P , et al.   Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure) . Circulation . 2004;110:975–981
  196. Applefeld MM , Newman KA , Grove WR , et al.   Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure . Am J Cardiol . 1983;51:455–458
  197. Cesario D , Clark J , Maisel A . Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study . Am Heart J . 1998;135:121–129
  198. Leier CV , Binkley PF . Parenteral inotropic support for advanced congestive heart failure . Prog Cardiovasc Dis . 1998;41:207–224
  199. Marius-Nunez AL , Heaney L , Fernandez RN , et al.   Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure . Am Heart J . 1996;132:805–808
  200. Oliva F , Latini R , Politi A , et al.   Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial . Am Heart J . 1999;138:247–253
  201. Teerlink JR , Jalaluddin M , Anderson S , et al.  PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators   Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death . Circulation . 2000;101:40–46
  202. Uretsky BF , Jessup M , Konstam MA , et al.  Enoximone Multicenter Trial Group   Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure (Lack of benefit compared with placebo) . Circulation . 1990;82:774–780
  203. Woods TD , Prisant LM . Pulsed inotropic therapy in chronic congestive heart failure: a review of the literature . Am J Ther . 2000;7:375–380
  204. Young JB , Moen EK . Outpatient parenteral inotropic therapy for advanced heart failure . J Heart Lung Transplant . 2000;19(suppl):S49–S57
  205. Krell MJ , Kline EM , Bates ER , et al.   Intermittent ambulatory dobutamine infusions in patients with severe congestive heart failure . Am Heart J . 1986;112:787–791
  206. Elis A , Bental T , Kimchi O , Ravid M , Lishner M . Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study . Clin Pharmacol Ther . 1998;63:682–685
  207. DiBianco R , Shabetai R , Kostuk W , et al.   A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure . N Engl J Med . 1989;320:677–683
  208. Cohn JN , Goldstein SO , Greenberg BH , et al.   A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure . Vesnarinone Trial InvestigatorsN Engl J Med . 1998;339:1810–1816
  209. DiBianco R , Shabetai R , Silverman BD , Leier CV , Benotti JR . Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study . J Am Coll Cardiol . 1984;4:855–866
  210. The Xamoterol in Severe Heart Failure Study Group . Xamoterol in severe heart failure . Lancet . 1990;336:1–6
  211. Hampton JR , Van Veldhuisen DJ , Kleber FX , et al.  Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators   Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure . Lancet . 1997;349:971–977
  212. Packer M , Carver JR , Rodeheffer RJ , et al.  The PROMISE Study Research Group   Effect of oral milrinone on mortality in severe chronic heart failure . N Engl J Med . 1991;325:1468–1475
  213. Terracciano CM , Hardy J , Birks EJ , Khaghani A , Banner NR , Yacoub MH . Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy . Circulation . 2004;109:2263–2265
  214. Dor V . Surgical remodeling of left ventricle . Surg Clin N Am . 2004;84:27–43
  215. Mann DL , Acker MA , Jessup M , Sabbah HN , Starling RC , Kubo SH . Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York Heart Association class III–IV heart failure . J Card Fail . 2004;10:185–192
  216. Shelton RJ , Velavan P , Nikitin NP , et al.   Clinical trials update from the American Heart Association meeting: ACORN-CSD, primary care trial of chronic disease management, PEACE, CREATE, SHIELD, A-HeFT, GEMINI, vitamin E meta-analysis, ESCAPE, CARP, and SCD-HeFT cost-effectiveness study . Eur J Heart Fail . 2005;7:127–135
  217. Soran O . A new treatment modality in heart failure enhanced external counterpulsation (EECP) . Cardiol Rev . 2004;12:15–20
  218. Soran O , Kennard ED , Kelsey SF , Holubkov R , Strobeck J , Feldman AM . Enhanced external counterpulsation as treatment for chronic angina in patients with left ventricular dysfunction: a report from the International EECP Patient Registry (IEPR) . Congest Heart Fail . 2002;8:297–302
  219. Hassink RJ , Dowell JD , de la Brutel RA , Doevendans PA , Field LJ . Stem cell therapy for ischemic heart disease . Trends Mol Med . 2003;9:436–441
  220. Kizana E , Alexander IE . Cardiac gene therapy: therapeutic potential and current progress . Curr Gene Ther . 2003;3:418–451
  221. Orlic D , Kajstura J , Chimenti S , et al.   Bone marrow cells regenerate infarcted myocardium . Nature . 2001;410:701–705
  222. Orlic D , Kajstura J , Chimenti S , et al.   Mobilized bone marrow cells repair the infarcted heart, improving function and survival . Proc Natl Acad Sci USA . 2001;98:10344–10349
  223. Perin EC , Dohmann HF , Borojevic R , et al.   Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure . Circulation . 2003;107:2294–2302
  224. Tse HF , Kwong YL , Chan JK , Lo G , Ho CL , Lau CP . Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation . Lancet . 2003;361:47–49
  225. Alderman EL , Fisher LD , Litwin P , et al.   Results of coronary artery surgery in patients with poor left ventricular function (CASS) . Circulation . 1983;68:785–795
  226. Shah PJ , Hare DL , Raman JS , et al.   Survival after myocardial revascularization for ischemic cardiomyopathy: a prospective ten-year follow-up study . J Thorac Cardiovasc Surg . 2003;126:1320–1327
  227. Joyce D , Loebe M , Noon GP , et al.   Revascularization and ventricular restoration in patients with ischemic heart failure: the STICH trial . Curr Opin Cardiol . 1997;18:454–457
  228. Athanasuleas CL , Buckberg GD , Stanley AW , et al.   Surgical ventricular restoration in the treatment of congestive heart failure due to postinfarction ventricular dilation . J Am Coll Cardiol . 2004;44:1439–1445
  229. Dor V . Reconstructive left ventricular surgery for postischemic akinetic dilatation . Semin Thorac Cardiovasc Surg . 1997;9:139–145
  230. Di DM , Sabatier M , Dor V , et al.   Effects of the Dor procedure on left ventricular dimension and shape and geometric correlates of mitral regurgitation one year after surgery . J Thorac Cardiovasc Surg . 2001;121:91–96
  231. Bach DS , Bolling SF . Improvement following correction of secondary mitral regurgitation in end-stage cardiomyopathy with mitral annuloplasty . Am J Cardiol . 1996;78:966–969
  232. Wu AH , Aaronson KD , Bolling SF , Pagani FD , Welch K , Koelling TM . Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitatiomortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction . J Am Coll Cardiol . 2005;45:381–387
  233. Mehra MR , Griffith BP . Is mitral regurgitation a viable treatment target in heart failure? (The plot just thickened) . J Am Coll Cardiol . 2005;45:388–390
  234. Remme WJ , Swedberg K  Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology . Comprehensive guidelines for the diagnosis and treatment of chronic heart failure . Eur J Heart Fail . 2002;4:11–22
  235. Packer M , Poole-Wilson PA , Armstrong PW , et al.  ATLAS Study Group   Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure . Circulation . 1999;100:2312–2318
  236. Carson P , Ziesche S , Johnson G , Cohn JN  Vasodilator–Heart Failure Trial Study Group . Racial differences in response to therapy for heart failure: analysis of the vasodilator–heart failure trials . J Card Fail . 1999;5:178–187
  237. Omland T , Aakvaag A , Bonarjee VV , et al.   Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction (Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide) . Circulation . 1996;93:1963–1969
  238. Hartmann F , Packer M , Coats AJ , et al.   Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial . Circulation . 2004;110:1780–1786
  239. Maisel A . B-type natriuretic peptide levels: a potential novel “white count” for congestive heart failure . J Card Fail . 2001;7:183–193
  240. McCullough PA , Nowak RM , McCord J , et al.   B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study . Circulation . 2002;106:416–422
  241. Gardner RS , Ozalp F , Murday AJ , Robb SD , McDonagh TA . N-terminal pro-brain natriuretic peptide (A new gold standard in predicting mortality in patients with advanced heart failure) . Eur Heart J . 2003;24:1735–1743
  242. Bruins S , Fokkema MR , Romer JW , et al.   High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure . Clin Chem . 2004;50:2052–2058
  243. Troughton RW , Frampton CM , Yandle TG , Espiner EA , Nicholls MG , Richards AM . Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations . Lancet . 2000;355:1126–1130
  244. Antman EM . Decision making with cardiac troponin tests . N Engl J Med . 2002;346:2079–2082
  245. Ishii J , Nomura M , Nakamura Y , et al.   Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure . Am J Cardiol . 2002;89:691–695
  246. Perna ER , Macin SM , Canella JP , et al.   Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification . Circulation . 2004;110:2376–2382
  247. Ishii J , Cui W , Kitagawa F , et al.   Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure . Clin Chem . 2003;49:2020–2026
  248. Campana C , Gavazzi A , Berzuini C , et al.   Predictors of prognosis in patients awaiting heart transplantation . J Heart Lung Transplant . 1993;12:756–765
  249. Aaronson KD , Schwartz JS , Chen TM , Wong KL , Goin JE , Mancini DM . Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation . Circulation . 1997;95:2660–2667
  250. Gardner RS , Henderson G , McDonagh TA . The prognostic use of right heart catheterization data in patients with advanced heart failure: how relevant are invasive procedures in the risk stratification of advanced heart failure in the era of neurohormones? . J Heart Lung Transplant . 2005;24:303–309
  251. Steimle AE , Stevenson LW , Chelimsky-Fallick C , et al.   Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure . Circulation . 1997;96:1165–1172
  252. Stevenson LW , Dracup KA , Tillisch JH . Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation . Am J Cardiol . 1989;63:461–464
  253. Binanay C , Califf RM , Hasselblad V , et al.   Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial . JAMA . 2005;294:1625–1633
  254. Kirklin JK , Naftel DC , Kirklin JW , Blackstone EH , White-Williams C , Bourge RC . Pulmonary vascular resistance and the risk of heart transplantation . J Heart Transplant . 1998;7:331–336
  255. Chen JM , Levin HR , Michler RE , Prusmack CJ , Rose EA , Aaronson KD . Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality . J Thorac Cardiovasc Surg . 1997;114:627–634
  256. Costard-Jackle A , Fowler MB . Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group . J Am Coll Cardiol . 1992;19:48–54
  257. Dreyfus G , Jebara VA , Guillemain R , Amrein C , Carpentier AF . Improved evaluation of pulmonary vascular resistance prior to heart transplantation . Transplant Proc . 1989;21:2559–2561
  258. Pagani FD , Lynch W , Swaniker F , et al.   Extracorporeal life support to left ventricular assist device bridge to heart transplant: a strategy to optimize survival and resource utilization . Circulation . 1999;100(suppl II):II-206–II-210
  259. Frazier OH , Rose EA , Oz MC , et al.   Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation . J Thorac Cardiovasc Surg . 2001;122:1186–1195
  260. Rose EA , Gelijns AC , Moskowitz AJ , et al.   Long-term mechanical left ventricular assistance for end-stage heart failure . N Engl J Med . 2001;345:1435–1443
  261. Michalsen A , Konig G , Thimme W . Preventable causative factors leading to hospital admission with decompensated heart failure . Heart . 1998;80:437–441
  262. Rich MW , Beckham V , Wittenberg C , et al.   A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure . N Engl J Med . 1995;333:1190–1195
  263. Stewart S , Marley JE , Horowitz JD . Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study . Lancet . 1999;354:1077–1083
  264. McAlister FA , Stewart S , Ferrua S , McMurray JJ . Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials . J Am Coll Cardiol . 2004;44:810–819
  265. DeBusk RF , Miller NH , Parker KM , et al.   Care management for low-risk patients with heart failure: a randomized, controlled trial . Ann Intern Med . 2004;141:606–613
  266. Atienza F , Anguita M , Martinez-Alzamora N , et al.   Multicenter randomized trial of a comprehensive hospital discharge and outpatient heart failure management program . Eur J Heart Fail . 2004;6:643–652
  267. Tsuyuki RT , McKelvie RS , Arnold JM , et al.   Acute precipitants of congestive heart failure exacerbations . Arch Intern Med . 2001;161:2337–2342

 Reprint requests: Amanda Rowe, Executive Director, ISHLT, 14673 Midway Road, Suite 200, Addison, TX 75001. E-mail: amanda.rowe@ishlt.org

PII: S1053-2498(06)00459-1

doi: 10.1016/j.healun.2006.06.007

The Journal of Heart and Lung Transplantation
Volume 25, Issue 9 , Pages 1003-1023 , September 2006

Article Tools